Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
Obinutuzumab is a potent anti-B cell drug already approved to treat lupus nephritis, chronic lymphocytic leukemia, and follicular lymphoma. Therapies targeting B cells are perhaps the most effective ...
The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results